Hochster HS - Search Results

1

Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.

Catenacci DVT, Kang YK, Park H, Uronis HE, Lee KW, Ng MCH, Enzinger PC, Park SH, Gold PJ, Lacy J, Hochster HS, Oh SC, Kim YH, Marrone KA, Kelly RJ, Juergens RA, Kim JG, Bendell JC, Alcindor T, Sym SJ, Song EK, Chee CE, Chao Y, Kim S, Lockhart AC, Knutson KL, Yen J, Franovic A, Nordstrom JL, Li D, Wigginton J, Davidson-Moncada JK, Rosales MK, Bang YJ; CP-MGAH22-5 Study Group. Catenacci DVT, et al. Among authors: hochster hs. Lancet Oncol. 2020 Aug;21(8):1066-1076. doi: 10.1016/S1470-2045(20)30326-0. Epub 2020 Jul 9. Lancet Oncol. 2020. PMID: 32653053 Clinical Trial.

2

A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.

Jacobs C, Lyman G, Velez-García E, Sridhar KS, Knight W, Hochster H, Goodnough LT, Mortimer JE, Einhorn LH, Schacter L, et al. Jacobs C, et al. J Clin Oncol. 1992 Feb;10(2):257-63. doi: 10.1200/JCO.1992.10.2.257. J Clin Oncol. 1992. PMID: 1732427 Clinical Trial.

3

A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer.

Schilsky RL, Bukowski R, Burris H 3rd, Hochster H, O'Rourke M, Wall JG, Mani S, Bonny T, Levin J, Hohneker J. Schilsky RL, et al. Ann Oncol. 2000 Apr;11(4):415-20. doi: 10.1023/a:1008356522080. Ann Oncol. 2000. PMID: 10847459 Free article. Clinical Trial.

4

Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer.

Mani S, Hochster H, Beck T, Chevlen EM, O'Rourke MA, Weaver CH, Bell WN, White R, McGuirt C, Levin J, Hohneker J, Schilsky RL, Lokich J. Mani S, et al. J Clin Oncol. 2000 Aug;18(15):2894-901. doi: 10.1200/JCO.2000.18.15.2894. J Clin Oncol. 2000. PMID: 10920138 Clinical Trial.

5

A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer.

Ramanathan RK, Picus J, Raftopoulos H, Bernard S, Lockhart AC, Frenette G, Macdonald J, Melin S, Berg D, Brescia F, Hochster H, Cohn A. Ramanathan RK, et al. Cancer Chemother Pharmacol. 2008 Mar;61(3):453-8. doi: 10.1007/s00280-007-0489-5. Epub 2007 May 22. Cancer Chemother Pharmacol. 2008. PMID: 17516069 Clinical Trial.

6

FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity.

Gunturu KS, Yao X, Cong X, Thumar JR, Hochster HS, Stein SM, Lacy J. Gunturu KS, et al. Among authors: hochster hs. Med Oncol. 2013 Mar;30(1):361. doi: 10.1007/s12032-012-0361-2. Epub 2012 Dec 28. Med Oncol. 2013. PMID: 23271209 Review.

7

Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer.

Shah MA, Wainberg ZA, Catenacci DV, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP. Shah MA, et al. Among authors: hochster hs. PLoS One. 2013;8(3):e54014. doi: 10.1371/journal.pone.0054014. Epub 2013 Mar 14. PLoS One. 2013. PMID: 23516391 Free PMC article. Clinical Trial.

8

Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients.

Rubinson DA, Hochster HS, Ryan DP, Wolpin BM, McCleary NJ, Abrams TA, Chan JA, Iqbal S, Lenz HJ, Lim D, Rose J, Bekaii-Saab T, Chen HX, Fuchs CS, Ng K. Rubinson DA, et al. Among authors: hochster hs. Invest New Drugs. 2014 Feb;32(1):113-22. doi: 10.1007/s10637-013-9956-5. Epub 2013 Apr 9. Invest New Drugs. 2014. PMID: 23568716 Free PMC article. Clinical Trial.

9

Phase II Study of Modified FOLFOX6 With Bevacizumab in Metastatic Gastroesophageal Adenocarcinoma.

Li J, Yao X, Kortmansky JS, Fischbach NA, Stein S, Deng Y, Zhang Y, Doddamane I, Karimeddini D, Hochster HS, Lacy J. Li J, et al. Among authors: hochster hs. Am J Clin Oncol. 2017 Apr;40(2):146-151. doi: 10.1097/COC.0000000000000114. Am J Clin Oncol. 2017. PMID: 25144267 Clinical Trial.

10

Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.

Hochster HS, Uboha N, Messersmith W, Gold PJ, ONeil BH, Cohen D, Denlinger C, Cohen S, Leichman CG, Leichman L, Lenz HJ. Hochster HS, et al. Cancer Chemother Pharmacol. 2015 Jan;75(1):17-23. doi: 10.1007/s00280-014-2609-3. Epub 2014 Oct 17. Cancer Chemother Pharmacol. 2015. PMID: 25322874 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

238 results

Search Page

Filters